新一代细菌性阴道炎治疗药物塞克硝唑的药理与临床

Pharmacological effects and clinical evaluation of secnidazole:a next-generation antimicrobial agent for bacterial vaginosis treatment

塞克硝唑是新一代硝基咪唑类药物,已经在欧洲、亚洲、南美洲和非洲等31个国家上市30多年。2017年9月15日,美国食品药品监督管理局(FDA)批准本品颗粒制剂上市,用于治疗成年女性的细菌性阴道炎。现对其作用机制、药动学、临床评价及安全性等进行综述。

Secnidazole, a next-generation 5-nitroimidazole, has been commercially available for more than three decades, with current approvals in 31 countries within Europe, Asia, South America and Africa. The US FDA recently approved a novel granule formulation of secnidazole for the treatment of adult female bacterial vaginitis. The mechanism, pharmacological actions, related clinical researches about the efficacy and safety of secnidazole were reviewed in this paper.